Enanta Pharmaceuticals

ENTA

Market cap $402M

13.87 USD

+0.16

1.17%

At close Updated Apr 29, 4:00 PM EDT

Pre-market

After hours

13.85

-0.02

0.14%

1 day

1.17%

5 days

0.58%

1 month

13.88%

3 months

7.52%

6 months

30.48%

Year to date

-3.81%

1 year

139.55%

5 years

-72.99%

10 years

-52.5%

About: Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Employees: 120

Healthcare Biotechnology